Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

September 28, 2022: The Panel on Opportunistic Infections in Adults and Adolescents (the Panel) updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below: Monkeypox: Added links to useful government and professional association websites.For a list of recent updates, please…

Read More

Updates to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

October 11, 2022: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has made revisions in the following sections of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection to address U.S. Food and Drug Administration approval of the dispersible tablet formulation of the fixed-dose combination…

Read More

Update to COVID-19 Treatment Guidelines: Changes Affecting People with HIV

February 7, 2022:  The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. The Panel periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the…

Read More

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

February 17, 2022: The Panel updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:  Mycobacterium tuberculosis Updated references and rationales. Updated drug–drug interactions. Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy. Clarified that, for the…

Read More